Cogent Biosciences, Inc.
bezuclastinib
NonAdvanced Systemic Mastocytosis
Countdown
176days
FDA decision · Dec 30, 2026
What's at stake
The FDA's approval decision on bezuclastinib for NonAdvanced Systemic Mastocytosis is due Dec 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“Acceptance of the NDA for bezuclastinib in NonAdvSM in February 2026”